source
- Vertex reports positive Phase 2b results for inaxaplin in APOL1-mediated kidney diseaseVertex Pharmaceuticals announced positive Phase 2b data for its kidney disease candidate inaxaplin, which targets APOL1-mediated kidney disease (AMKD). The Amplified trial enrolled two cohorts: 2…
- Boston life-science lab vacancy climbs to 31% as new spaces sit emptyVacancy rates for laboratory and manufacturing space in Massachusetts have surged dramatically, rising from around 3% in 2021 to roughly 31% by mid-2026, according to recent data. One high-profile…